Levitee Labs Inc. (CNSX:LVT) signed a memorandum of understanding to acquire BODIE Phytoceuticals Ltd. on December 1, 2020. On March 29, 2020, the Corporation entered into an agreement with BODIE to acquire a 15% equity stake in BODIE in exchange for 120,000 common shares of the Corporation at a deemed issue price of $0.25 per share. Levitee Labs Inc. (CNSX:LVT) acquired 15% stake in BODIE Phytoceuticals Ltd. on April 9, 2021.

With respect to the Company's acquisition of the remaining 85% interest in BODIE, as contemplated in the BODIE MOU, the Company continues to conduct due diligence and consider whether to pursue the transaction. The Corporation expects to consummate the BODIE Investment in early Q2, 2021